2. UroToday Home
  3. Trials in Progress

Trials in Progress

ARAMON: A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer

Trials in Progress

A 2-stage, Lead-in and Randomized, Phase 2, Open-label Study of Darolutamide Versus Enzalutamide as Monotherapy on Testosterone Levels Change in Men With Hormone-Naïve Prostate Cancer

  • Condition: Biochemically Recurrent Prostate Cancer
  • Study ID: NCT05526248
View Trial
Conference Coverage
Conference Highlights Written by Physician-Scientist
Presented by Andrew Laccetti, MD, MS
(UroToday.com) The 2024 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to a prostate cancer trials in progress poster session. Dr. Andrew Laccetti presented ARAMON, a phase 2, randomized, open-label study comparing darolutamide and enzalutamide monotherapy’s effects on serum testosterone levels in patients with castration-sensitive prostate cancer in the setting of biochemical recurrence.
Presented by Xin Gao, MD
(UroToday.com) The 2023 ASCO annual meeting included a prostate cancer session, featuring a trials in progress presentation by Dr. Xin Gao discussing ARAMON, a phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer.